TrialStem cell research & therapy2022

Safety of DW-MSC infusion in patients with low clinical risk COVID-19 infection: a randomized, double-blind, placebo-controlled trial.

Muhammad Karyana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.